ArticleGynecologic oncology reports2026
Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Objective: Somatic HER2 mutations occur in up to 6% of cervical cancer patients and are associated with poor prognosis. We explored the activity of trastuzumab deruxtecan (T-DXd) as a novel targeted therapy against HER2-mutated primary cervical cancer cell lines and xenografts with low HER2 expression. Methods: HER2 expression was assessed by flow cytometry, while Results: All eight primary cell lines available demonstrated low HER2 expression. CVX4 (HER2-S310F activating mutation) was significantly more sensitive to T-DXd than control antibody-drug conjugate (CTL-ADC) as demonstrated in the cytotoxicity experiments ( Conclusions: T-DXd was shown to be highly active against HER2-S310F-mutated cervical cancer cell lines and xenografts. T-DXd may represent a novel, effective therapeutic option for recurrent cervical cancer patients harboring mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.